No, 5 mg daily is NOT the correct dose for preventing recurrent PE
Eliquis (apixaban) 5 mg daily (once daily dosing) is incorrect and will not provide adequate anticoagulation for PE prevention. The FDA-approved dosing for reduction in risk of recurrent DVT and PE is 2.5 mg twice daily after completing at least 6 months of initial treatment 1.
Critical Dosing Error to Avoid
You appear to be asking about 5 mg once daily, which is not an approved regimen. The confusion likely stems from these distinct dosing schedules:
Correct FDA-Approved Dosing for PE 1:
Initial Treatment Phase (first 7 days):
- 10 mg twice daily
Continuation Treatment (after 7 days):
- 5 mg twice daily (not once daily)
Extended Secondary Prevention (after ≥6 months of treatment):
- 2.5 mg twice daily
Why Twice-Daily Dosing Matters
Apixaban has a half-life requiring twice-daily administration to maintain therapeutic anticoagulation. Taking 5 mg only once daily would result in:
- Subtherapeutic drug levels for significant portions of each 24-hour period
- Inadequate protection against recurrent thromboembolism
- Treatment failure
Evidence for Reduced-Dose Extended Therapy
The 2.5 mg twice-daily dose for extended prevention is supported by strong evidence. In cancer-associated VTE, reduced-dose apixaban (2.5 mg twice daily) after initial full-dose treatment was noninferior to full-dose (5 mg twice daily) for preventing recurrent VTE while significantly reducing bleeding (adjusted subhazard ratio 0.75; 95% CI 0.58-0.97) 2.
The American Society of Hematology 2020 guidelines note that both standard-dose and lower-dose DOACs may be used for secondary prevention, though this is a conditional recommendation based on moderate-certainty evidence 3. The European Society of Cardiology recommends NOACs (including apixaban) over warfarin for PE treatment 4.
Clinical Bottom Line
If you are considering extended anticoagulation after completing initial PE treatment, use apixaban 2.5 mg twice daily, not 5 mg once daily. The once-daily regimen provides inadequate anticoagulation and is not FDA-approved for any indication. If still within the initial 6-month treatment period, continue 5 mg twice daily after the first week of 10 mg twice daily 1.